Acuvi (ACUVI) Business Update summary

Company overview and leadership

• Specializes in motion precision technology, serving med tech, life science, semicon, and lab automation sectors, with expansion into areas like nuclear physics and space.

• Works closely with customers, often directly, to develop tailored solutions, though distributors are used in some regions.

• New CEO Nils Sjöholm brings a strong background in med tech, sales, and global business, and was previously an investor in the company.

Strategic initiatives and sales transformation

• Shifting from distributor-based sales to direct sales in the US and Europe to improve margins and customer engagement.

• Retaining distributors in Asia due to cultural and market complexities, with plans to better support and train them.

• Direct sales expected to yield higher margins and more customers, with early involvement in customer projects leading to better solutions and repeat business.

Financial targets and performance

• EBITDA targets: SEK 52–55 million for 2025, SEK 65 million (25–30% margin) for 2026, and SEK 85 million for 2027 remain in place.

• Recently became cash flow positive, providing a strong foundation for future growth.

• Board will communicate if targets are at risk; current outlook is optimistic but acknowledges aggressive timelines.